apricus wealth LLC Has $2.12 Million Stock Holdings in Novartis AG (NYSE:NVS)

apricus wealth LLC lifted its stake in Novartis AG (NYSE:NVS) by 2.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,813 shares of the company’s stock after acquiring an additional 600 shares during the period. apricus wealth LLC’s holdings in Novartis were worth $2,123,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Steigerwald Gordon & Koch Inc. grew its stake in shares of Novartis by 4.8% in the third quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock worth $241,000 after acquiring an additional 95 shares during the last quarter. Centaurus Financial Inc. grew its stake in shares of Novartis by 1.7% in the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock worth $659,000 after acquiring an additional 98 shares during the last quarter. FLC Capital Advisors grew its stake in shares of Novartis by 4.4% in the third quarter. FLC Capital Advisors now owns 2,366 shares of the company’s stock worth $272,000 after acquiring an additional 100 shares during the last quarter. Clear Harbor Asset Management LLC grew its stake in shares of Novartis by 2.3% in the third quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company’s stock worth $509,000 after acquiring an additional 100 shares during the last quarter. Finally, Allen Wealth Management LLC grew its stake in shares of Novartis by 1.8% in the third quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock worth $666,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Performance

Novartis stock opened at $99.93 on Friday. The stock has a 50-day simple moving average of $100.15 and a 200 day simple moving average of $108.75. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. Novartis AG has a 12-month low of $92.35 and a 12-month high of $120.92. The stock has a market capitalization of $204.25 billion, a price-to-earnings ratio of 11.61, a P/E/G ratio of 1.42 and a beta of 0.57.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The business had revenue of $12.82 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same period in the previous year, the business posted $1.74 earnings per share. On average, research analysts anticipate that Novartis AG will post 7.62 earnings per share for the current fiscal year.

Analyst Ratings Changes

NVS has been the subject of several research reports. Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. BMO Capital Markets raised their target price on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a research report on Wednesday, October 30th. Finally, HSBC cut Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Two analysts have rated the stock with a sell rating and six have given a hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.